GSK (OTC: GLAXF) leaders add shares via company reward plan
Filing Impact
Filing Sentiment
Form Type
6-K
GSK plc filed a report showing several senior leaders acquiring small amounts of GSK ordinary shares through the company’s Share Reward Plan. On 2025-10-09, CEO Emma Walmsley acquired 14 ordinary shares (7 partnership and 7 matching shares) at £16.4083 per share on the London Stock Exchange. CFO Julie Brown, Group General Counsel James Ford, President Corporate Development David Redfern, President Global Supply Chain Regis Simard, President Global Affairs Philip Thomson, and ViiV Healthcare CEO and President Global Health Deborah Waterhouse each acquired 16 shares under the plan at the same price. SVP Global Communications Sally Jackson and SVP & Company Secretary Victoria Whyte each acquired 14 shares on the same terms.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma Walmsley
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
7 (partnership shares)
|
|
||
|
|
£16.4083
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
14 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Julie Brown
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
James Ford
|
|||
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sally Jackson
|
|||
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
7 (partnership shares)
|
|
||
|
|
£16.4083
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
14 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President, Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Regis Simard
|
|||
|
b)
|
Position/status
|
President, Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Philip Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Deborah Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
8 (partnership shares)
|
|
||
|
|
£16.4083
|
8 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
16 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
SVP & Company Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4083
|
7 (partnership shares)
|
|
||
|
|
£16.4083
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
14 Ordinary Shares
£16.4083
|
||||
|
e)
|
Date
of the transaction
|
2025-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
10, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
FAQ
What insider transactions did GSK (GLAXF) report in this filing?
The filing reports multiple GSK senior executives acquiring small amounts of ordinary shares under the company’s Share Reward Plan, all executed on 2025-10-09 on the London Stock Exchange.
How many GSK shares did CEO Emma Walmsley acquire?
Emma Walmsley acquired a total of 14 ordinary shares, consisting of 7 partnership shares and 7 matching shares, at a price of £16.4083 per share.
What did GSK CFO Julie Brown purchase under the Share Reward Plan?
Julie Brown acquired 16 ordinary shares in total, comprising 8 partnership shares and 8 matching shares, at £16.4083 per share under GSK’s Share Reward Plan.
Which other GSK executives acquired shares and in what amounts?
James Ford, David Redfern, Regis Simard, Philip Thomson, and Deborah Waterhouse each acquired 16 ordinary shares. Sally Jackson and Victoria Whyte each acquired 14 ordinary shares, all via the Share Reward Plan.
What type of GSK security was acquired and on which market?
The executives acquired GSK ordinary shares of 31 ¼ pence each (ISIN GB00BN7SWP63), and the transactions were conducted on the London Stock Exchange (XLON).
At what price were the GSK ordinary shares acquired by management?
All reported acquisitions were made at a price of £16.4083 per ordinary share under the company’s Share Reward Plan.
Is this GSK filing related to a share sale or a purchase by insiders?
The transactions disclosed are acquisitions of GSK ordinary shares by senior executives through the company’s Share Reward Plan, not sales.